We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Novavax Inc (NVAX) USD0.01

Sell:$15.49 Buy:$15.50 Change: $0.35 (2.31%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.35 (2.31%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.35 (2.31%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Contact details

700 Quince Orchard Road
United States
+1 (240) 2682000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.18 billion
Shares in issue:
140.42 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • John Jacobs
    President, Chief Executive Officer, Director
  • John Trizzino
    President, Chief Operating Officer
  • James Kelly
    Chief Financial Officer, Executive Vice President, Treasurer
  • Filip Dubovsky
    President - Research and Development
  • John Herrmann
    Executive Vice President
  • Elaine O'hara
    Executive Vice President, Chief Strategy Officer
  • Gale Smith
    Senior Vice President - Discovery and Pre-Clinical Research, Chief Scientist
  • Mark Casey
    Chief Legal Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.